1. Gill JS, Georgiou M, Kalitzeos A, Moore AT, Michaelides M. 
Progressive cone and cone-rod dystrophies: clinical features, 
molecular genetics and prospects for therapy. British Journal of 
Ophthalmology. 2019;103(5):711-20.
DOI:10.1136/bjophthalmol-2018-313278
2. Maugeri A, Klevering BJ, Rohrschneider K, Blankenagel A, 
Brunner HG, Deutman AF, et al. Mutations in the ABCA4 (ABCR) 
gene are the major cause of autosomal recessive cone-rod 
dystrophy. The American Journal of Human Genetics. 
2000;67(4):960-6.
DOI:10.1086/303079
3. Caba L, Florea L, Braha EE, Lupu VV, Gorduza EV. Monitoring and 
management of Bardet-Biedl syndrome: what the multidisciplinary team can do. Journal of Multidisciplinary Healthcare. 
2022:2153-67.
DOI:10.2147/JMDH.S274739
4. Choudhury AR, Munonye I, Sanu KP, Islam N, Gadaga C. A review 
of Alström syndrome: a rare monogenic ciliopathy. Intractable & 
rare diseases research. 2021;10(4):257-62.
DOI:10.5582/irdr.2021.01113
5. Hearn T. ALMS1 and Alström syndrome: a recessive form of 
metabolic, neurosensory and cardiac deficits. Journal of Molecular 
Medicine. 2019;97(1):1-17.
DOI:10.1007/s00109-018-1714-x
6. Delmaghani S, El-Amraoui A. The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms 
to a new classification. Human Genetics. 2022;141(3):709-
35.
DOI:10.1007/s00439-022-02448-7
7. Meire F, Van Genderen M, Lemmens K, Ens-Dokkum M. 
Thiamine-responsive megaloblastic anemia syndrome 
(TRMA) with cone-rod dystrophy. Ophthalmic genetics. 
2000;21(4):243-50. DOI:10.1076/1381-
6810(200012)2141-HFT243
8. Mabrouk A, Aburawi EH. Thiamine-Responsive 
Megaloblastic Anemia Syndrome Combined with 
Thalassemia Trait: A Rare Association. Ibnosina Journal of 
Medicine and Biomedical Sciences. 2023;15(04):183-7.
DOI:10.1055/s-0043-1772821
9. Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, 
Pearce DA, Weimer JM. Therapeutic landscape for Batten 
disease: current treatments and future prospects. Nature 
Reviews Neurology. 2019;15(3):161-78.
DOI:10.1038/s41582-019-0138-8
10. Brudvig JJ, Weimer JM. CLN7 gene therapy: hope for an 
ultra-rare condition. The Journal of Clinical Investigation. 
2022;132(5).
DOI:10.1172/JCI157820
11. Waszczykowska A, Jeziorny K, Barańska D, Matera K, 
Pyziak-Skupien A, Ciborowski M, et al. Searching for 
Effective Methods of Diagnosing Nervous System Lesions 
in Patients with Alström and Bardet-Biedl Syndromes. 
Genes. 2023;14(9):1784.
DOI:10.3390/genes14091784
12. Birtel J, Eisenberger T, Gliem M, Müller PL, Herrmann 
P, Betz C, et al. Clinical and genetic characteristics of 251 
consecutive patients with macular and cone/cone-rod 
dystrophy. Scientific reports. 2018;8(1):4824.
DOI:10.1038/s41598-018-22096-0
13. Tatour Y, Ben-Yosef T. Syndromic inherited retinal 
diseases: genetic, clinical and diagnostic aspects. 
Diagnostics. 2020;10(10):779.
DOI:10.3390/diagnostics10100779
14. Hosseini SM, Nejad Shahrokh Abadi R, Babaei M, 
Eghbal F, Hashemi N. Cone-Rod Dystrophy and 
Progressive Visual Loss as the First Manifestation of 
Neuronal Ceroid Lipofuscinosis Type 7: A Case Report. 
Clin Case Rep. 2024;12(11):e9566.
DOI:10.1002/ccr3.9566
15. Chen X, Dong T, Hu Y, Shaffo FC, Belur NR, Mazzulli JR, 
et al. AAV9/MFSD8 gene therapy is effective in preclinical 
models of neuronal ceroid lipofuscinosis type 7 disease. 
The Journal of clinical investigation. 2022;132(5).
DOI:10.1172/JCI146286
16. Mole SE. 1067 The Neuronal Ceroid Lipofuscinoses. 
2024 [cited 11/22/2024]. In: Jasper's Basic Mechanisms 
of the Epilepsies [Internet]. Oxford University Press, [cited 
11/22/2024]; [0]. Available from: 
https://doi.org/10.1093/med/9780197549469.003.005
0.DOI:10.1093/med/9780197549469.003.0050
17. Thompson DA, Handley SE, Henderson RH, Marmoy 
OR, Gissen P. An ERG and OCT study of neuronal ceroid 
lipofuscinosis CLN2 Battens retinopathy. Eye. 
2021;35(9):2438-48.
DOI:10.1038/s41433-021-01594-y
18. Dyken PR. Reconsideration of the classification of the 
neuronal ceroid-lipofuscinoses. Am J Med Genet Suppl. 
1988;5:69-84. DOI:10.1002/ajmg.1320310610
19. Kohan R, Cismondi IA, Kremer RD, Muller VJ, Guelbert 
N, Anzolini VT, et al. An integrated strategy for the 
diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) 
and 2 (CLN2) in eleven Latin American patients. Clin 
Genet. 2009;76(4):372-82.
DOI:10.1111/j.1399-0004.2009.01214.x
20. Lourenço CM, Sallum JMF, Pereira AM, Girotto PN, Kok 
F, Vilela DRF, et al. A needle in a haystack? The impact of a 
targeted epilepsy gene panel in the identification of a 
treatable but rapidly progressive metabolic epilepsy: 
CLN2 disease. Arq Neuropsiquiatr. 2024;82(5):1-8.
DOI:10.1055/s-0044-1786854
21. L.G K. Clinical - genetic characteristics of neuronal 
ceroid lipofuscinosis type 2. Neuroscience and Neurological 
Surgery. 2020.
DOI:10.31579/2578-8868/129
22. Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M. 
Bardet-Biedl syndrome: current perspectives and clinical outlook. 
Therapeutics and Clinical Risk Management. 2023:115-32.
DOI:10.2147/TCRM.S338653
23. Elawad OAMA, Dafallah MA, Ahmed MMM, Albashir AAD, 
Abdalla SMA, Yousif HHM, et al. Bardet-Biedl syndrome: a case 
series. Journal of medical case reports. 2022;16(1):169.
DOI:10.1186/s13256-022-03396-6
24. La Spada AR. Spinocerebellar ataxia type 7. 2020.
25. Martin J-J. Spinocerebellar ataxia type 7. Handbook of clinical 
neurology. 2012;103:475-91.
DOI:10.1016/B978-0-444-51892-7.00030-9
25. Jalili IK. Cone-rod dystrophy and amelogenesis imperfecta 
(Jalili syndrome): phenotypes and environs. Eye. 
2010;24(11):1659-68.
DOI:10.1038/eye.2010.144
26. Parry DA, Mighell AJ, El-Sayed W, Shore RC, Jalili IK, Dollfus H, 
et al. Mutations in CNNM4 cause Jalili syndrome, consisting of 
autosomal-recessive cone-rod dystrophy and amelogenesis 
imperfecta. Am J Hum Genet. 2009;84(2):266-73.
DOI:10.1016/j.ajhg.2009.01.009
27. Hirji N, Bradley PD, Li S, Vincent A, Pennesi ME, Thomas AS, et 
al. Jalili Syndrome: Cross-sectional and Longitudinal Features of 
Seven Patients With Cone-Rod Dystrophy and Amelogenesis 
Imperfecta. Am J Ophthalmol. 2018;188:123-30.
DOI:10.1016/j.ajo.2018.01.029
28. Jalili IK. Cone-rod dystrophy and amelogenesis imperfecta 
(Jalili syndrome): phenotypes and environs. Eye (Lond). 
2010;24(11):1659-68.
DOI:10.1038/eye.2010.144
29. Smith CE, Poulter JA, Antanaviciute A, Kirkham J, Brookes SJ, 
Inglehearn CF, et al. Amelogenesis imperfecta; genes, proteins, and 
pathways. Frontiers in physiology. 2017;8:435.
DOI:10.3389/fphys.2017.00435
30. Rattanapornsompong K, Rinkrathok M, Sriwattanapong K, 
Shotelersuk V, Porntaveetus T. Functional and pathogenic insights 
into CNNM4 variants in Jalili syndrome. Sci Rep. 
2024;14(1):29091.
DOI:10.1038/s41598-024-80720-8
31. Luder HU, Gerth-Kahlert C, Ostertag-Benzinger S, Schorderet 
DF. Dental phenotype in Jalili syndrome due to a c. 1312 dupC 
homozygous mutation in the CNNM4 gene. PloS one. 
2013;8(10):e78529.
DOI:10.1371/journal.pone.0078529
32. Almeida FT, Carneiro-Freitas R, Caldas R, Vieira AP. 
Hypotrichosis with juvenile macular dystrophy. International 
Journal of Trichology. 2018;10(5):234-6.
DOI:10.4103/ijt.ijt_60_18
33. Klötzer C, Schnabel F, Kubasch A-S, Jentzsch M, Franke G-N, 
Uhlig J, et al. Thiamine-Responsive Megaloblastic Anemia 
Syndrome Mimicking Myelodysplastic Neoplasm. Acta 
Haematologica. 2025;148(4):380-5.
DOI:10.1159/000542286
34. Yasemin E. Thiamine Responsive Megaloblastic Anemia 
Syndrome: A Novel Mutation and Review 2 of Turkish Patients. 
Ann Clin Case Rep 2023; 8.2498.
35. Di Candia F, Di Iorio V, Tinto N, Bonfanti R, Iovino C, Rosanio 
FM, et al. An Italian case series' description of thiamine responsive 
megaloblastic anemia syndrome: importance of early diagnosis 
and treatment. Ital J Pediatr. 2023;49(1):158.
DOI:10.1186/s13052-023-01553-1
36. Toms M, Pagarkar W, Moosajee M. Usher syndrome: clinical 
features, molecular genetics and advancing therapeutics. 
Therapeutic advances in ophthalmology. 
2020;12:2515841420952194.
DOI:10.1177/2515841420952194
37. Tahani N, Maffei P, Dollfus H, Paisey R, Valverde D, Milan G, et 
al. Consensus clinical management guidelines for Alström 
syndrome. Orphanet journal of rare diseases. 2020;15:1-22.
DOI:10.1186/s13023-020-01468-8
38. Wierzbicki AS, Lloyd MD, Schofield CJ, Feher MD, Gibberd FB. 
Refsum's disease: a peroxisomal disorder affecting phytanic acid α‐oxidation. Journal of neurochemistry. 2002;80(5):727-35.39. Van Den Brink DM, Brites P, Haasjes J, Wierzbicki AS, 
Mitchell J, Lambert-Hamill M, et al. Identification of PEX7 
as the second gene involved in Refsum disease. The 
American Journal of Human Genetics. 2003;72(2):471-7.
DOI:10.1086/346093
40. Jansen GA, Waterham HR, Wanders RJ. Molecular basis 
of Refsum disease: sequence variations in phytanoyl‐CoA 
hydroxylase (PHYH) and the PTS2 receptor (PEX7). 
Human mutation. 2004;23(3):209-18.
DOI:10.1002/humu.10315
41. Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher MD, 
Wierzbicki AS. The effectiveness of long-term dietary 
therapy in the treatment of adult Refsum disease. Journal 
of Neurology, Neurosurgery & Psychiatry. 
2010;81(9):954-7.
DOI:10.1136/jnnp.2008.161059
42. Rodrigues JM, Fernandes HD, Caruthers C, Braddock 
SR, Knutsen AP. Cohen syndrome: review of the literature. 
Cureus. 2018;10(9).
DOI:10.7759/cureus.3330
43. Chandler K, Kidd A, Al-Gazali L, Kolehmainen J, 
Lehesjoki A-E, Black GC, et al. Diagnostic criteria, clinical 
characteristics, and natural history of Cohen syndrome. 
Journal of medical genetics. 2003;40(4):233-41.
DOI:10.1136/jmg.40.4.233
44. Quinn MP, MacKeen LD, Vincent A, Strube YNJ. Early 
ocular findings in Cohen syndrome: Case report and 
Canadian survey study. Canadian Journal of 
Ophthalmology. 2021;56(1):e26-e8.
DOI:10.1016/j.jcjo.2020.07.011
45. Falk MJ, Feiler HS, Neilson DE, Maxwell K, Lee JV, Segall 
SK, et al. Cohen syndrome in the Ohio Amish. American 
Journal of Medical Genetics Part A. 2004;128(1):23-8.
DOI:10.1002/ajmg.a.30033
46. Güneş N, Alkaya DU, Demirbilek V, Yalçınkaya C, 
Tüysüz B. Early diagnostic signs and the natural history of 
typical findings in cohen syndrome. The Journal of 
Pediatrics. 2023;252:93-100.
DOI:10.1016/j.jpeds.2022.08.052
47. Simms RJ, Hynes AM, Eley L, Sayer JA. 
Nephronophthisis: a genetically diverse ciliopathy. 
International journal of nephrology. 
2011;2011(1):527137.
DOI:10.4061/2011/527137
48. Jellouli M, Gargah T. Senior Loken syndrome. The Pan 
African Medical Journal. 2015;22:141-.
DOI:10.11604/pamj.2015.22.141.8042
PMid:26889322 PMCid:PMC4742040
49. Georges B, Cosyns J-P, Dahan K, Snyers B, Carlier B, 
Loute G, et al. Late-onset renal failure in Senior-Loken 
syndrome. American journal of kidney diseases. 
2000;36(6):1271-5.
DOI:10.1053/ajkd.2000.19845
50. O'connor M, Gallagher D, Mulloy E. Jeune syndrome. 
Postgraduate medical journal. 2008;84(996):559-.
DOI:10.1136/pgmj.2007.066159
51. De Vries J, Yntema J, Van Die C, Crama N, Cornelissen E, 
Hamel B. Jeune syndrome: description of 13 cases and a proposal 
for follow-up protocol. European journal of pediatrics. 
2010;169:77-88.
DOI:10.1007/s00431-009-0991-3
52. Poyner SE, Bradshaw WT. Jeune syndrome: considerations for 
management of asphyxiating thoracic dystrophy. Neonatal 
Network. 2013;32(5):342-52.
DOI:10.1891/0730-0832.32.5.342
53. Tan W, Lin A, Keppler-Noreuil K. Cranioectodermal dysplasia. 
2021.
54. Lin AE, Traum AZ, Sahai I, Keppler‐Noreuil K, Kukolich MK, 
Adam MP, et al. Sensenbrenner syndrome (Cranioectodermal 
dysplasia): clinical and molecular analyses of 39 patients including 
two new patients. American Journal of Medical Genetics Part A. 
2013;161(11):2762-76.
DOI:10.1002/ajmg.a.36265
55. Sajovic J, Meglič A, Volk M, Maver A, Jarc-Vidmar M, Hawlina M, 
et al. Stargardt-like clinical characteristics and disease course 
associated with variants in the WDR19 gene. Genes. 
2023;14(2):291.
DOI:10.3390/genes14020291
56. Parisi MA. The molecular genetics of Joubert syndrome and 
related ciliopathies: The challenges of genetic and phenotypic 
heterogeneity. Translational science of rare diseases. 2019;4(1-
2):25-49.
DOI:10.3233/TRD-190041
57. Parisi M, Glass I. Joubert syndrome. 2017.
58. Spahiu L, Behluli E, Grajçevci-Uka V, Liehr T, Temaj G. Joubert 
syndrome: molecular basis and treatment. Journal of Mother and 
Child. 2022;26(1):118-23.
59. Suzuki T, Miyake N, Tsurusaki Y, Okamoto N, Alkindy A, Inaba 
A, et al. Molecular genetic analysis of 30 families with Joubert 
syndrome. Clinical Genetics. 2016;90(6):526-35.
DOI:10.1111/cge.12836
60. Chang K-J, Wu H-Y, Yarmishyn AA, Li C-Y, Hsiao Y-J, Chi Y-C, et 
al. Genetics behind cerebral disease with ocular comorbidity: 
finding parallels between the brain and eye molecular pathology. 
International Journal of Molecular Sciences. 2022;23(17):9707.
DOI:10.3390/ijms23179707
61. Murray SJ, Mitchell NL. Ocular therapies for neuronal ceroid 
lipofuscinoses: more than meets the eye. Neural Regen Res. 
2022;17(8).
DOI:10.4103/1673-5374.332148
62. Corti S, Kim KH, Chen T, Botezatu A, Cora V, Ma K, et al. 
Recreating pathophysiology of CLN2 disease and demonstrating 
reversion by TPP1 gene therapy in hiPSC-derived retinal 
organoids and retina-on-chip. Cell Reports Medicine. 
2025;6(8):102244.
DOI:10.1016/j.xcrm.2025.102244
63. Nebbioso M, Artico M, Gharbiya M, Mannocci A, Limoli PG, 
Iannetta D, et al. State of the Art on Inherited Retinal Dystrophies: 
Management and Molecular Genetics. J Clin Med. 2025;14(10).
DOI:10.3390/jcm14103526
64. Murro V, Banfi S, Testa F, Iarossi G, Falsini B, Sodi A, et al. A 
multidisciplinary approach to inherited retinal dystrophies from 
diagnosis to initial care: a narrative review with inputs from 
clinical practice. Orphanet J Rare Dis. 2023;18(1):223.
DOI:10.1186/s13023-023-02798-z